Financials et MD&A published Friday 5th 2024For those who have access to Stochwatch: (worth you time reading the document for the investment)
https://www.stockwatch.com/News/Sedardoc/5543005.pdf
https://www.stockwatch.com/News/Sedardoc/5543004.pdf
Revenue $ 23,899 Year Ended Y July 31, 2023
General and administrative expenses increased to $1,571,646 (2022 - $783,848) mainly due to increased operations fees related to AI4LYF licensing agreement, partially offset by decreased management fees
9. Accounts payable and accrued liabilities
As at July 31, 2023 July 31, 2022
Accounts payable and accrued liabilities $ 1,432,467 $ 335,603
Amounts due to related parties (Du to Fia) 641,890 807,459
Total accounts payable and accrued liabilities $ 2,074,357 $ 1,143,062
For fiscal 2024 the Company’s operating expenses are estimated to be $175,000 per month for recurring corporate operating costs
The Company will be required to raise additional capital in order to meet its ongoing operating expenses and complete its planned research and development on all of its current devices for the twelve-month period ending July 31, 2024
Respiratory Disease portfolio
AI4LYF Digital Cough Technology
InStatin - novel inhaled treatment asthma & COPD
Vascular Disease Portfolio
Inretio -Ischemic stroke treatment
Venowave – Deep Vein Thrombosis Treatment Device(DVT)
Consumer Health Portfolio
AcuVid™ Covid-19 Rapid Antigen Saliva Test
Benepod - Contrast Therapy Device
TheroZAP™ - Thermal Therapy Device
InterceptCS ™- Cold Sore Prevention System
PREVA™ CLOT RETRIEVER The first and only protective blood clot retriever using a distal basket. PREVA™ is the only blood clot retrieval device that can access distally to the clot. The device protects the brain during the procedure from sub-clots by “ensnaring“ the clot and encapsulating it using our PREVA Basket. This allows the complete removal of the clot and its fragments to ensure revascularization of the brain tissue.
• GLP COMPLETED: Good Lab (GLP) Animal Study completed in May 2023 - The PREVA™ device achieved overall removal of 100% of the clot in 100% of the cases during the GLP study
• FIH: Inretio has received regulatory approval for First-in-Human (FIH) Trial approval from the Israeli Ministry of Health to conduct a human study at Sheba Hospital for its Preva® ischemic stroke solution.